National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 11475-11476 [2017-03531]
Download as PDF
Federal Register / Vol. 82, No. 35 / Thursday, February 23, 2017 / Notices
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Syed M Quadri, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6210,
MSC 7804, Bethesda, MD 20892, 301–435–
1211, quadris@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Emerging Technologies in
Neuroscience.
Date: March 24, 2017.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Sharon S Low, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5104,
MSC 5104, Bethesda, MD 20892–5104, 301–
237–1487, lowss@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: February 17, 2017.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03528 Filed 2–22–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
patent applications listed below may be
obtained by communicating with the
indicated licensing contact at the
Technology Transfer and Intellectual
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
rmajette on DSK2TPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
14:10 Feb 22, 2017
Jkt 241001
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
CD300b Expression Exacerbates
Endotoxemia and Septic Peritonitis
Description of Technology: The innate
immune system is the first line of host
defense against invading pathogens.
Lipopolysaccharides (LPS), present in
gram-negative bacteria membranes,
cause strong immune responses
following detection by the Toll-like
receptor 4 (TLR4) on immune cells. This
detection results in the release of proinflammatory cytokines, such as tumor
necrosis factor alpha, interleukin-6, and
interferon gamma, to assist with
clearance of the infectious insult. In
parallel, interleukin-10 (IL–10), an antiinflammatory cytokine, is induced to
limit the immune response. This is
because unchecked immune activation
leads to a more severe
immunopathology, such as septic shock
and subsequently death. Current
therapies to treat sepsis are ineffective,
and clinical trials based on
neutralization of specific inflammatory
cytokines have failed.
The inventors, listed below, have
discovered that CD300b is a LPS
binding receptor. This interaction
results in a reduced IL–10 production,
leading to an amplification of lethal
inflammation. In vitro, anti-CD300b
antibodies block LPS binding to
CD300b, stopping association with
TLR4 and CD14 and increases IL–10
levels. In vivo, administration of antiCD300b antibodies protects animals
from septic shock, due to a reduce level
of pro-inflammatory cytokines but
subsequent increase in the antiinflammatory cytokine, IL–10.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
As a means of treating endotoxemia and
septic peritonitis.
Competitive Advantages: No current
therapeutics are available to treat septic
shock.
Development Stage: Pre-clinical.
Inventors:
John E. Coligan, NIAID, NIH
Oliver H. Voss, NIAID, NIH
Konrad Krzewski, NIAID, NIH
Publications: Voss, Oliver H., et al.
‘‘Lipopolysaccharide-induced CD300b
receptor binding to toll-like receptor 4
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
11475
alters signaling to drive cytokine
responses that enhance septic shock.’’
Immunity 44.6 (2016): 1365–1378.
Intellectual Property: HHS Reference
No. E–112–2016/0—U.S. Patent
Application No. 62/308,144 filed 03/14/
2016.
Licensing Contact: Chris Kornak, 240–
627–3705, chris.kornak@nih.gov.
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further co-develop CD300b antagonists.
For collaboration opportunities, please
contact Chris Kornak, 240–627–3705,
chris.kornak@nih.gov.
Dated: February 16, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–03452 Filed 2–22–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, Elucidation of Mechanisms
of Radiation-Induced Endovascular Injury
and Development of Treatments/Mitigators
for Radiation-Induced Endothelial Cell and
Vascular Dysfunction (U01).
Date: March 16–17, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892,
(Telephone Conference Call).
Contact Person: Zhuqing (Charlie) Li,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
E:\FR\FM\23FEN1.SGM
23FEN1
11476
Federal Register / Vol. 82, No. 35 / Thursday, February 23, 2017 / Notices
Activities, Room # 3G41B, National Institutes
of Health/NIAID, 5601 Fishers Lane,
MSC9823, Bethesda, MD 20892–9823, (240)
669–5068, zhuqing.li@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 17, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–03531 Filed 2–22–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Brian Makela,
Chemist, Substance Abuse and Mental Health
Services Administration.
Substance Abuse and Mental Health
Services Administration
[FR Doc. 2017–03480 Filed 2–22–17; 8:45 am]
rmajette on DSK2TPTVN1PROD with NOTICES
Center for Substance Abuse
Prevention: Notice of Meeting
BILLING CODE 4162–20–P
Pursuant to Pub. L. 92–463, notice is
hereby given that the Substance Abuse
and Mental Health Services
Administration’s (SAMHSA) Center for
Substance Abuse Prevention (CSAP)
Drug Testing Advisory Board (DTAB)
will meet in person and via web
conference on March 20, 2017, from
9:00 a.m. to 5:00 p.m. EDT and March
21, 2017 from 9:00 a.m. to 2:00 p.m.
EDT.
The Board will meet in open session
on March 20, 2017, from 9:00 a.m. to
2:00 p.m. , to provide updates on the
Mandatory Guidelines for Federal
Workplace Drug Testing Programs,
provide data on hair testing programs
currently in use in the private sector,
research data on marijuana edibles, and
the most current data from Quest
Diagnostics Drug Testing Index.
The board will meet in closed session
on March 20, 2017, from 2:00 p.m. to
5:00 p.m. EDT and on March 21, 2017,
from 9:00 a.m. to 2:00 p.m. EDT to hear
about current confidential practices in
the hair testing industry, and to discuss
proposals for the Oral Fluid Mandatory
Guidelines for Federal Workplace Drug
Testing Programs. Therefore, these
portions of the meeting are closed to the
public as determined by the
Administrator, SAMHSA, in accordance
with 5 U.S.C. 552b(c)(4) and (9)(B), and
5 U.S.C. App. 2, Section 10(d).
Meeting information and a roster of
DTAB members may be obtained by
accessing the SAMHSA Advisory
Committees Web site, https://
www.samhsa.gov/about-us/advisorycouncils/drug-testing-advisory-boarddtab, or by contacting Brian Makela.
Committee Name: Substance Abuse
and Mental Health Services
VerDate Sep<11>2014
14:10 Feb 22, 2017
Jkt 241001
Administration’s Center for Substance
Abuse Prevention Drug Testing
Advisory Board.
Dates/Time/Type: March 20, 2016,
from 9:00 a.m. to 2:00 p.m., EDT: OPEN.
March 20, 2016, from 2:00 p.m. to 5:00
p.m., EDT: CLOSED. March 21, 2016,
from 9:00 a.m. to 2:00 p.m., EDT:
CLOSED.
Place: Parklawn Building, Room
5W07, 5600 Fishers Lane, Rockville,
Maryland 20857.
Contact: Brian Makela, Division of
Workplace Programs, 5600 Fishers Lane,
Room 16N02B, Rockville, Maryland
20857, Telephone: 240–276–2600, Fax:
240–276–2610, Email: brian.makela@
samhsa.hhs.gov.
DEPARTMENT OF HOMELAND
SECURITY
U.S. Citizenship and Immigration
Services
[OMB Control Number 1615—NEW
Agency Information Collection
Activities: Independent Evaluation of
the Systematic Alien Verification for
Entitlements (SAVE) Program, Form
G–1503; New Collection
U.S. Citizenship and
Immigration Services, Department of
Homeland Security.
ACTION: 60-Day Notice.
AGENCY:
The Department of Homeland
Security (DHS), U.S. Citizenship and
Immigration (USCIS) invites the general
public and other Federal agencies to
comment upon this proposed new
collection of information. In accordance
with the Paperwork Reduction Act
(PRA) of 1995, the information
collection notice is published in the
Federal Register to obtain comments
regarding the nature of the information
collection, the categories of
respondents, the estimated burden (i.e.
the time, effort, and resources used by
the respondents to respond), the
estimated cost to the respondent, and
the actual information collection
instruments.
SUMMARY:
Comments are encouraged and
will be accepted for 60 days until April
24, 2017.
ADDRESSES: All submissions received
must include the OMB Control Number
1615–NEW in the body of the letter, the
DATES:
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
agency name and Docket ID USCIS–
2016–0007. To avoid duplicate
submissions, please use only one of the
following methods to submit comments:
(1) Online. Submit comments via the
Federal eRulemaking Portal Web site at
https://www.regulations.gov under eDocket ID number USCIS–2016–0007;
(2) Mail. Submit written comments to
DHS, USCIS, Office of Policy and
Strategy, Chief, Regulatory Coordination
Division, 20 Massachusetts Avenue
NW., Washington, DC 20529–2140.
FOR FURTHER INFORMATION CONTACT:
USCIS, Office of Policy and Strategy,
Regulatory Coordination Division,
Samantha Deshommes, Chief, 20
Massachusetts Avenue NW.,
Washington, DC 20529–2140, telephone
number 202–272–8377 (This is not a
toll-free number. Comments are not
accepted via telephone message). Please
note contact information provided here
is solely for questions regarding this
notice. It is not for individual case
status inquiries. Applicants seeking
information about the status of their
individual cases can check Case Status
Online, available at the USCIS Web site
at https://www.uscis.gov, or call the
USCIS National Customer Service
Center at 800–375–5283 (TTY 800–767–
1833).
SUPPLEMENTARY INFORMATION:
Comments
You may access the information
collection instrument with instructions,
or additional information by visiting the
Federal eRulemaking Portal site at:
https://www.regulations.gov and enter
USCIS–2016–0007 in the search box.
Regardless of the method used for
submitting comments or material, all
submissions will be posted, without
change, to the Federal eRulemaking
Portal at https://www.regulations.gov,
and will include any personal
information you provide. Therefore,
submitting this information makes it
public. You may wish to consider
limiting the amount of personal
information that you provide in any
voluntary submission you make to DHS.
DHS may withhold information
provided in comments from public
viewing that it determines may impact
the privacy of an individual or is
offensive. For additional information,
please read the Privacy Act notice that
is available via the link in the footer of
https://www.regulations.gov.
Written comments and suggestions
from the public and affected agencies
should address one or more of the
following four points:
(1) Evaluate whether the proposed
collection of information is necessary
E:\FR\FM\23FEN1.SGM
23FEN1
Agencies
[Federal Register Volume 82, Number 35 (Thursday, February 23, 2017)]
[Notices]
[Pages 11475-11476]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-03531]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious
Diseases Special Emphasis Panel, Elucidation of Mechanisms of
Radiation-Induced Endovascular Injury and Development of Treatments/
Mitigators for Radiation-Induced Endothelial Cell and Vascular
Dysfunction (U01).
Date: March 16-17, 2017.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 5601 Fishers Lane,
Rockville, MD 20892, (Telephone Conference Call).
Contact Person: Zhuqing (Charlie) Li, Ph.D., Scientific Review
Officer, Scientific Review Program, Division of Extramural
[[Page 11476]]
Activities, Room # 3G41B, National Institutes of Health/NIAID, 5601
Fishers Lane, MSC9823, Bethesda, MD 20892-9823, (240) 669-5068,
zhuqing.li@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: February 17, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-03531 Filed 2-22-17; 8:45 am]
BILLING CODE 4140-01-P